SEARCH:   Advanced

Blood, 1 November 2003, Vol. 102, No. 9, pp. 3241-3243. Prepublished online as a Blood First Edition Paper on July 10, 2003; DOI 10.1182/blood-2003-05-1616. This Article Abstract Full Text (PDF) All Versions of this Article: 2003-05-1616v1 102/9/3241    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Scheiflinger, F. Articles by Rieger, M. Search for Related Content PubMed PubMed Citation Articles by Scheiflinger, F. Articles by Rieger, M. Related Collections Hemostasis, Thrombosis, and Vascular Biology Cell Adhesion and Motility Brief Reports Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Brief report Nonneutralizing IgM and IgG antibodies to von Willebrand factor–cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura Friedrich Scheiflinger, Paul Knöbl, Bettina Trattner, Barbara Plaimauer, Gabriele Mohr, Michael Dockal, Friedrich Dorner, and Manfred Rieger From Baxter BioScience, Biomedical Research Center, 2304 Orth/Donau, Austria; and Department of Medicine 1, Division of Hematology and Blood Coagulation, University of Vienna, Austria.    Abstract Top Abstract Introduction Study design Results and discussion References   Acquired thrombotic thrombocytopenic purpura (TTP) has been linked to severe deficiency of ADAMTS-13 activity caused by autoantibodies inhibitory to ADAMTS-13. We report data on a patient with confirmed TTP who had severely reduced ADAMTS-13 activity but showed no ADAMTS-13 inhibition in a widely used fluid phase activity assay. With a newly developed enzyme-linked immunosorbent assay, using immobilized recombinant ADAMTS-13, we found high titers of IgM and IgG antibodies that bound to ADAMTS-13, but did not neutralize protease activity. These autoantibodies probably influenced the half-life of ADAMTS-13 or its binding to the endothelial cell surface, thereby compromising ADAMTS-13 activity in vivo. Given that ADAMTS-13 may interact physiologically with various receptors or ligands, the occurrence, distribution, and the epitope mapping of nonneutralizing antibodies will be an important area for future research.    Introduction Top Abstract Introduction Study design Results and discussion References   von Willebrand factor (VWF) is proteolytically degraded by a specific VWF-cleaving metalloprotease,1,2 recently termed ADAMTS-13.3 Reduced activity of ADAMTS-13 results in the persistence of unusually large VWF (ULVWF)4-6 that can induce platelet aggregation7 and the formation of platelet- and VWF-rich thrombi under high shear stress conditions.8 Thrombotic thrombocytopenic purpura (TTP), a devastating disease characterized by microangiopathic hemolytic anemia and thrombocytopenia,9 is characterized by severe (< 5%) reduced ADAMTS-13 activity.10 The hereditary form of TTP has been related to specific gene mutations in the ADAMTS13 locus resulting in severe ADAMTS-13 deficiency.11 Acquired TTP has been attributed to autoantibodies that inhibit ADAMTS-13 activity.12-14 Analytically, acquired TTP can be discriminated from hereditary TTP by the detection of inhibitory antibodies using assays measuring ADAMTS-13 proteolytic activity in vitro.12,13 In these assays, the high shear stress found in arterial capillaries is mimicked by the presence of urea that leads to ADAMTS-13 activity under nonphysiologic conditions.1 Absence of inhibitory antibodies is suggestive of hereditary TTP, whereas the presence of inhibitory antibodies implies TTP mediated by autoimmune antibodies. The gene encoding human ADAMTS13 was recently cloned3,15 and ADAMTS-13 was shown to be the enzyme responsible for the proteolytic degradation of VWF in plasma.16,17 Data suggest that in vivo ADAMTS-13 is active while bound to the endothelial cell surface.18 Other mechanisms, apart from direct protease activity inhibition by autoantibodies, could therefore play a part in causing TTP. For instance, ADAMTS-13 activity might be inhibited by autoantibodies that prevent enzyme binding to endothelial cell surfaces or antibodies that block interactions with cellular or plasmatic modulators, which are necessary for full enzymatic activity in vivo.19 Another possibility is that nonneutralizing antibodies reduce the absolute amount of circulating ADAMTS-13 in the plasma by antibody-mediated clearance.    Study design Top Abstract Introduction Study design Results and discussion References   For the enzyme-linked immunosorbent assay (ELISA)–based anti–ADAMTS-13 antibody detection in plasma, recombinant ADAMTS-13 was C-terminal His-tagged by the addition of 6 histidine codons to the cDNA and stably expressed in HEK 293 cells (human embryonic kidney fibroblasts; CRL-1573, American Type Culture Collection, Manassas, VA). Protein purification was done by immobilized metal chelate affinity chromatography. His-tagged ADAMTS-13 (2 µg, 2-fold excess) was immobilized on the surface of ELISA (Nunc Maxi Sorb; Nalge Nunc International, Rochester, NY) plate by an anti–His-tag antibody (Qiagen, Hilden, Germany). The patient's plasma was diluted in the range from 1:20 up to 1:1200 in phosphate-buffered saline (PBS)/2% wt/vol bovine serum albumin (BSA) and added to the immobilized protease. After several washing steps (PBS/0.1% vol/vol Tween), bound anti–ADAMTS-13 IgG antibodies were detected by phosphatase-labeled secondary antibodies specifically binding the constant region of human IgG (Sigma-Aldrich, Steinheim, Germany). In a separate experiment, antibodies binding to the human µ chain (Sigma-Aldrich) were used to detect anti–ADAMTS-13 IgM antibodies. Both detection antibodies were specific for their immunoglobulin classes and no cross-reaction was observed. Normal human plasma (NHP) was used as control. The standard deviation (SD) was calculated from several lots of NHP. The cut-off point above which we considered the dilution to be positive was the value obtained for the NHP in the particular experiment plus 2 times the SD calculated from the several NHP lots.    Results and discussion Top Abstract Introduction Study design Results and discussion References   We report data on a 70-year-old woman who was admitted to the hospital after suffering progressive neurologic derangement for several days. The symptoms increased, and the patient became confused and somnolent. The patient gave informed consent for blood sampling, and the study was performed according to the guidelines defined in the Declaration of Helsinki. Laboratory analysis showed severe thrombocytopenia (9 G/L) and Coombs-negative hemolysis (red blood cell count, 2.6 x 10–9/L; hemoglobin, 7.5 g/dL; reticulocyte count, 181 x 10–6/L; lactate dehydrogenase [LDH], 2410 U/mL; bilirubin, 2.6 mg/dL; haptoglobin, < 12 mg/dL) with red cell fragmentation (47 schistocytes/1000 red cells). The patient was fever free but had arterial hypertension. Her renal function was normal (creatinine, 1.07 mg/dL). This constellation suggested acquired TTP. Plasma exchange therapy (40 mL/kg body weight daily), supplemented with prednisone (1 mg/kg body weight daily) and packed red cells, was started immediately. Platelet concentrates were avoided. After the third plasma exchange her platelet count increased to 60 x 10–6/L, her LDH normalized, and the neurologic disturbance ceased. Although the patient responded to plasma exchange therapy she experienced at least 7 relapses within the following 2 months. Additional treatment consisted of corticosteroids and protein A immunoadsorption (which resulted in a short-term success); finally a splenectomy was performed. The patient died 64 days after the initial diagnosis during another fulminant relapse of TTP. Examination of the patient's plasma on admission showed a high VWF:Ag level (3.2 U/mL). Neither ULVWF polymers nor high-molecular-weight VWF multimers were detectable in a sodium dodecyl sulfate–agarose analysis (data not shown). Using a quantitative immunoblot assay1 and a collagen-binding ELISA after ADAMTS-13–induced digestion of VWF,20 ADAMTS-13 activity was found to be severely reduced (< 0.03 U/mL). Samples of the patient's plasma and purified IgG and IgG-depleted fractions from the plasma were repeatedly screened for ADAMTS-13–inhibiting antibodies but no inhibitory antibodies could be detected, which was surprising because the patient's clinical presentation strongly supported a diagnosis of acquired TTP. We next analyzed the patient's plasma for anti–ADAMTS-13 antibodies that do not neutralize ADAMTS-13 proteolytic activity, but still bind to ADAMTS-13. We used 2 newly developed ELISAs and found high titers of anti–ADAMTS-13 IgG antibodies ( 1:600; Figure 1A) and of anti–ADAMTS-13 IgM antibodies ( 1:400; Figure 1B) in the patient's plasma, but not in the control plasma. View larger version (15K): [in this window] [in a new window]   Figure 1.. Anti–ADAMTS-13 antibodies detected in an ADAMTS-13 antigen-specific ELISA system. NHP was used as a control. The error bars of the NHP indicate the 2 times added SD calculated from several plasma lots. Plasma dilutions ranging from 1:20 to 1:1200 were analyzed. (A) Anti–ADAMTS-13 IgG titer. (B) Anti–ADAMTS-13 IgM titer.   Our data most likely indicate an early stage of TTP during which plasma VWF levels are increased, but ULVWF and high-molecular-weight VWF are undetectable because they are consumed and deposited during platelet aggregation.21 In accordance with the current pathophysiologic hypothesis,19 we found a severe reduction of ADAMTS-13 proteolytic activity, but we could not detect inhibiting antibodies. Thus, we have shown that IgM and IgG antibodies are present in plasma from a TTP patient and that these antibodies react with ADAMTS-13, but do not inhibit its activity. A possible explanation is that the antibodies bind to regions of the protein that are not necessary for exerting protease activity under the conditions of the in vitro assay. In vivo they could, however, lead to increased clearance of the protease-antibody complexes or interfere with protease binding to the endothelial cell surface, where cleavage of ULVWF probably occurs, or both. On the other hand, we cannot rule out the possibility of the presence of an inhibitor, just sufficient to neutralize enzyme activity in vivo but below the assay's detection limit in vitro. In summary, the lack of ADAMTS-13 activity in acquired TTP is frequently attributed to the presence of an autoantibody inhibiting ADAMTS-13–mediated cleavage of ULVWF.12-14 We have been able to show the presence of anti–ADAMTS-13 antibodies (IgM and IgG) that do not neutralize ADAMTS-13 activity in standard assays, but most likely impair ADAMTS-13 activity by mechanisms different from merely blocking substrate-cleaving activity. The ELISA-based assay system we used is fast and very simple and may have a much greater sensitivity for detecting anti–ADAMTS-13 antibodies than the more complex standard in vitro assay. The discovery of the nonneutralizing antibodies could have a considerable impact on our understanding of the pathophysiology of TTP in general and in particular might be important for the diagnosis of hereditary TTP. In addition, our findings support clinical decisions to start plasma exchange therapy without delay in patients with clinically suspected TTP.    Acknowledgements   We thank Elise Langdon-Neuner for editing the manuscript.    Footnotes   Submitted May 22, 2003; accepted June 30, 2003. Prepublished online as Blood First Edition Paper, July 10, 2003; DOI 10.1182/blood-2003-05-1616. Seven authors (F.S., B.T., B.P., G.M., M.D., F.D., and M.R.) declare a financial interest in Baxter BioScience. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: Friedrich Scheiflinger, Baxter BioScience, Biomedical Research Center, Uferstrasse 15, 2304 Orth/Donau, Austria; e-mail: scheiff{at}baxter.com.    References Top Abstract Introduction Study design Results and discussion References   Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87: 4223-4234.[Abstract/Free Full Text] Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996;87: 4235-4244.[Abstract/Free Full Text] Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276: 41059-41063.[Abstract/Free Full Text] Moake JL, Rudy CK, Troll JH. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307: 1432-1435.[Medline] [Order article via Infotrieve] Moake JL, McPherson PD. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. Am J Med. 1989;87: 9N-15N.[CrossRef][Medline] [Order article via Infotrieve] Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997;89: 3097-3103.[Abstract/Free Full Text] Chow TW, Turner NA, Chintagumpala M. Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura. Am J Hematol. 1998;57: 293-302.[CrossRef][Medline] [Order article via Infotrieve] Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress induced platelet aggregation. J Clin Invest. 1986;78: 1456-1461.[Medline] [Order article via Infotrieve] Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc N Y Pathol Soc. 1924; 4: 21-24. Bianchi V, Robles R, Alberio L, Furlan M, Lämmle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 2002; 100: 710-713.[Abstract/Free Full Text] Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413: 488-494.[CrossRef][Medline] [Order article via Infotrieve] Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood. 1998;91: 2839-2846.[Abstract/Free Full Text] Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolyticuremic syndrome. N Engl J Med. 1998;339: 1578-1584.[Abstract/Free Full Text] Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998; 339: 1585-1594.[Abstract/Free Full Text] Soejima K, Mimura N, Hirashima M, et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem (Tokyo). 2001;130: 475-480.[Abstract/Free Full Text] Plaimauer B, Zimmermann K, Völkel D, et al. Cloning, expression, and functional chracterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood. 2002;100: 3626-3632.[Abstract/Free Full Text] Antoine G, Zimmermann K, Plaimauer B, et al. ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factorcleaving protease activity by recombinant human ADAMTS13. Br J Haematol. 2003;120: 821-824.[CrossRef][Medline] [Order article via Infotrieve] Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002;100: 4033-4039.[Abstract/Free Full Text] Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347: 589-600.[Free Full Text] Gerritsen HE, Turecek PL, Schwarz HP, Lämmle B, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost. 1999;82: 1386-1389.[Medline] [Order article via Infotrieve] Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res. 1985;38: 469-479.[CrossRef][Medline] [Order article via Infotrieve] CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: B. Lammle, J. A. Kremer Hovinga, and J. N. George Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease Haematologica, February 1, 2008; 93(2): 172 - 177. [Full Text] [PDF] S. Ferrari, F. Scheiflinger, M. Rieger, G. Mudde, M. Wolf, P. Coppo, J.-P. Girma, E. Azoulay, C. Brun-Buisson, F. Fakhouri, et al. Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity Blood, April 1, 2007; 109(7): 2815 - 2822. [Abstract] [Full Text] [PDF] P. M. Mannucci and F. Peyvandi TTP and ADAMTS13: When Is Testing Appropriate? Hematology, January 1, 2007; 2007(1): 121 - 126. [Abstract] [Full Text] [PDF] A. K. Chauhan, D. G. Motto, C. B. Lamb, W. Bergmeier, M. Dockal, B. Plaimauer, F. Scheiflinger, D. Ginsburg, and D. D. Wagner Systemic antithrombotic effects of ADAMTS13 J. Exp. Med., March 20, 2006; 203(3): 767 - 776. [Abstract] [Full Text] [PDF] J. E. Sadler Thrombotic Thrombocytopenic Purpura: A Moving Target Hematology, January 1, 2006; 2006(1): 415 - 420. [Abstract] [Full Text] [PDF] F. Fakhouri, J.-P. Vernant, A. Veyradier, M. Wolf, G. Kaplanski, R. Binaut, M. Rieger, F. Scheiflinger, P. Poullin, B. Deroure, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases Blood, September 15, 2005; 106(6): 1932 - 1937. [Abstract] [Full Text] [PDF] M. Rieger, P. M. Mannucci, J. A. K. Hovinga, A. Herzog, G. Gerstenbauer, C. Konetschny, K. Zimmermann, I. Scharrer, F. Peyvandi, M. Galbusera, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases Blood, August 15, 2005; 106(4): 1262 - 1267. [Abstract] [Full Text] [PDF] M. Galbusera, E. Bresin, M. Noris, S. Gastoldi, D. Belotti, C. Capoferri, E. Daina, P. Perseghin, F. Scheiflinger, F. Fakhouri, et al. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report Blood, August 1, 2005; 106(3): 925 - 928. [Abstract] [Full Text] [PDF] G. G. Levy, D. G. Motto, and D. Ginsburg ADAMTS13 turns 3 Blood, July 1, 2005; 106(1): 11 - 17. [Abstract] [Full Text] [PDF] M. Noris, S. Bucchioni, M. Galbusera, R. Donadelli, E. Bresin, F. Castelletti, J. Caprioli, S. Brioschi, F. Scheiflinger, G. Remuzzi, et al. Complement Factor H Mutation in Familial Thrombotic Thrombocytopenic Purpura with ADAMTS13 Deficiency and Renal Involvement J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1177 - 1183. [Abstract] [Full Text] [PDF] M.-A. Dragon-Durey, C. Loirat, S. Cloarec, M.-A. Macher, J. Blouin, H. Nivet, L. Weiss, W. H. Fridman, and V. Fremeaux-Bacchi Anti-Factor H Autoantibodies Associated with Atypical Hemolytic Uremic Syndrome J. Am. Soc. Nephrol., February 1, 2005; 16(2): 555 - 563. [Abstract] [Full Text] [PDF] J.-D. Studt, J. A. K. Hovinga, G. Antoine, M. Hermann, M. Rieger, F. Scheiflinger, and B. Lammle Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin Blood, January 15, 2005; 105(2): 542 - 544. [Abstract] [Full Text] [PDF] G. Ferretti, M. C. Petti, P. Carlini, M. Zeuli, A. Picardi, G. Meloni, E. Bria, P. Papaldo, A. Fabi, and F. Cognetti Zoledronic acid-associated thrombotic thrombocytopenic purpura Ann. Onc., December 1, 2004; 15(12): 1847 - 1848. [Full Text] [PDF] C. Klaus, B. Plaimauer, J.-D. Studt, F. Dorner, B. Lammle, P. M. Mannucci, and F. Scheiflinger Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura Blood, June 15, 2004; 103(12): 4514 - 4519. [Abstract] [Full Text] [PDF] X. L. Zheng, R. M. Kaufman, L. T. Goodnough, and J. E. Sadler Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura Blood, June 1, 2004; 103(11): 4043 - 4049. [Abstract] [Full Text] [PDF] J.-D. Studt, J. A. K. Hovinga, R. Radonic, V. Gasparovic, D. Ivanovic, M. Merkler, U. Wirthmueller, C. Dahinden, M. Furlan, and B. Lammle Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins Blood, June 1, 2004; 103(11): 4195 - 4197. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) All Versions of this Article: 2003-05-1616v1 102/9/3241    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Scheiflinger, F. Articles by Rieger, M. Search for Related Content PubMed PubMed Citation Articles by Scheiflinger, F. Articles by Rieger, M. Related Collections Hemostasis, Thrombosis, and Vascular Biology Cell Adhesion and Motility Brief Reports Social Bookmarking                   What's this?

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020